Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390437 | 0.87 | MAP2K1 (0.67) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391366 | 0.85 | MAP2K1 (0.61) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL390302 | 0.84 | MAP2K1 (0.60) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391241 | 0.83 | MAP2K1 (0.68) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL391056 | 0.82 | MAP2K1 (0.74) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL388473 | 0.82 | MAP2K1 (0.61) | MAP2K1 | |
| SCHEMBL393136 | 0.80 | MAP2K1 (0.57) | MAP2K1 | |
| SCHEMBL392380 | 0.78 | MAP2K1 (0.65) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL392129 | 0.78 | MAP2K1 (0.66) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL392465 | 0.76 | MAP2K1 (0.75) | MAP2K1ABCB11NQO2MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8268852-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268852-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8211921-B2 | Heterocyclic inhibitors of MEK and methods of use | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070293544-A1 | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | MERCK SERONO SA (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885ABCB11 2439/4885NQO2 288/4885 |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | MAP2K1 88/4885ABCB11 2381/4885NQO2 296/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 91/4885ABCB11 2522/4885NQO2 285/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | MAP2K1 45/4885ABCB11 3583/4885NQO2 279/4885 |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, MAPK9 | MAP2K1 85/4885ABCB11 2300/4885NQO2 260/4885 |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, CDK9 | MAP2K1 61/4885ABCB11 4039/4885NQO2 402/4885 |
| US-20070293544-A1 | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | BRAF, MAP3K19, MAPK1 | MAP2K1 65/4885ABCB11 2045/4885NQO2 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.